Hypothesis: Proteasomal dysfunction. A primary event in neurogeneration that leads to nitrative and oxidative stress and subsequent cell death

Annals of the New York Academy of Sciences

Volumn 962, Issue , 2002, Pages 182-194

  Halliwell, Barry ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Alzheimer's disease; Neurogeneration; Nitric oxide; Oxidative stress; Proteasome

Indexed keywords

NITROGEN DERIVATIVE; PROTEASOME; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; CONFERENCE PAPER; HUMAN; NERVE CELL NECROSIS; NERVE DEGENERATION; NITRATION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

EID: 0036268224     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04067.x     Document Type: Conference Paper

References (111)

1. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
2. Recent advances in the molecular pathogenesis of Friedreich ataxia
3. Translating cell biology into therapeutic advances in Alzheimer's disease
4. Mutant CuZn superoxide dismutase in motor neuron disease
5. Does failure of parkin-mediated ubiquitination cause juvenile parkinsonism?
6. Plaque-associated neuronal proteins: A recurrent motif in neuritic amyloid deposits throughout diverse cortical areas of the Alzheimer's disease brain
7. Free radical-mediated disruption of cellular ion homeostasis, mitochondrial dysfunction and neuronal degeneration in sporadic and inherited Alzheimer's disease
8. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease
9. Neuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer's disease brain
10. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: A central role for bound transition metals
11. Evidence of neuronal oxidative damage in Alzheimer's disease
12. Protein nitration in Parkinson's disease
13. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions
14. Oxidative stress and motor neurone disease
15. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis
16. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis
17. Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis
18. Aggregation of ubiquitin and a mutant ALS-linked SOD1 protein correlate with disease progression and fragmentation of the Golgi apparatus
19. Gain in functions of mutant Cu, Zn-superoxide dismutases as a causative factor in familial amyotrophic lateral sclerosis: Less reactive oxidant formation but high spontaneous aggregation and precipitation
20. α-synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components
21. Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models
22. The proteasome, a novel protease regulated by multiple mechanisms
23. Properties of the nuclear proteasome, activator PA28gamma (REGgamma)
24. Degradation of oxidised proteins in mammalian cells
25. Bioenergetics in Huntington's disease
26. Role of free radicals in the neurodegenerative diseases. Therapeutic implications for antioxidant treatment
27. NO evidence for increased oxidative damage to lipids, proteins, or DNA in Huntington's disease
28. Role of transgenic models for the study of oxidative neurotoxicity in Alzheimer's disease
29. Indices of oxidative stress in Parkinson's disease. Alzheimer's disease and dementia with Lewy bodies
30. Common mechanisms of oxidative damage in chronic neurodegenerative conditions: Potential points of therapeutic intervention
31. Increased 8, 12-iso-iPF2alpha-VI in Alzheimer's disease: Correlation of a non-invasive index of lipid peroxidation with disease severity
32. Increased CSF F2- isoprostane concentration in probable A.D.
33. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients
34. A role for 4-hydroxynonenal, an aldehyde product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide
35. Evidence that 4-bydroxynonenal mediates oxidative stress-induced neuronal apoptosis
36. 4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats
37. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer's disease is associated with APOE genotype
38. Monoclonal antibodies for detection of 4-hydroxynonenal modified proteins
39. Roles of lipid peroxidation in modulation of cellular signalling pathways, cell dysfunction, and death in the nervous system
40. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzbeimer's disease
41. In Alzheimer's Disease, Heine Oxygenase is Coincident with Alz50, an epitope of τ induced by 4-hydroxy-2-nonenal modification
42. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease
43. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients
44. Effect of the overexpression of wild type or mutant α-synuclein on cell susceptibility to insult
45. 2, 4-HNE or serum deprivation: Potentiation of injury by ALS-related mutant SODs and protection by bcl-2
46. Poly-ADP ribose polymerase activates nuclear proteasome to degrade oxidatively damaged histones
47. Age-related losses of cognitive function and motor skills in mice associated with oxidative protein damage in the brain
48. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer's disease
49. Decreased proteasome-mediated degradation I T cells from the elderly: A role in immune senescence
50. Possible involvement of proteasome inhibition in aging: Implications for oxidative stress
51. Age-related changes in the 20S and 26S proteasome activities in the liver of male F344 rats
52. Decreased levels of proteasome activity and proteasome expression in aging spinal cord
53. Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-alpha-phenylnitrone
54. Effects of age and caloric intake on protein oxidation in different brain regions and on behavioural functions of the mouse
55. Role of protein-bound carbonyl groups in the formation of advanced glycation endproducts
56. Advanced glycation end products ia Alzheimer's disease and other neurodegenerative diseases
57. Endogenous nitric oxide synthesis: Biological functions and pathphysiology
58. Role of nitric oxide in the control of mitochondrial function
59. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and the ugly
60. Nitric oxide and peroxynitrite. The ugly, the uglier and the not so good
61. Tyrosine nitration: Localization, quantification, consequences for protein function and signal transduction
62. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation
63. An activity in rat tissues that modifies nitrotyrosine-containing proteins
64. Peroxynitrite increases the degradation of aconitase and other cellular proteins by proteasome
65. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo, property of one familial ALS-linked superoxide dismutase 1 mutant
66. 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress
67. Proteasomal dysfunction induced by 4-hydroxy-2,3-transnonenal, an end-product of lipid peroxidation
68. Activation of the cell death programme by nitric oxide involves inhibition of the proteasome
69. Degradation of alpha-synuclein by proteasome
70. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis
71. Parkin is metabolised by the ubiquitin/proteasome system
72. Inhibition of the multicatalytic proteinase (proteasome) by 4-hydroxy-2-nonenal cross-linked protein
73. 4-Hydroxynonenal-modified amyloid-β peptide inhibits the proteasome: Possible importance in Alzheimer's disease
74. Molecular biology of the proteasome
75. Caspase-1 and -3 are subsequently activated in motor neuron death in Cu, Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis
76. Increased caspase 3 and bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease
77. Neuronal cell death in nervous system development, disease, and injury
78. Mitochondrial nitric oxide synthase, oxidative stress and apoptosis
79. Triggering and modulation of apoptosis by oxidative stress
80. Effect of proteasome inhibition on cellular oxidative damage and antioxidant defences
81. Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release
82. Impaired clearance of oxidised proteins in neurode-generative disease
83. Protein precipitation: A common etiology in neurodegenerative disorders?
84. Proteasome inhibitors activate stress kinases and induce Hsp72
85. Proteasomal function is impaired in substantia nigra in Parkinson's disease
86. Impaired proteasome function in Alzheimer's Disease
87. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly
88. Induction of nitric oxide - Dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase
89. Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-kappa B
90. Inhibitory and stimulatory effects of lactacystin on expression of nitric oxide synthase type 2 in brain glial cells. The role of Ikappa B-beta
91. Effect of overexpression of bcl-2 on cellular oxidative damage, nitric oxide production, antioxidant defenses and the proteasome system
92. Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis
93. Lactacystin, proteasome function and cell fate
94. Inhibition versus induction of apoptosis by proteasome inhibitors depends on concentration
95. Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-kappaB activation
96. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis and activates caspase-3 in cultured cerebellar granule cells
97. Proteasome inhibition results in increased poly-ADP-ribosylation: Implications for neuron death
98. Role of proteasome in Alzheimer's disease
99. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases
100. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia
101. Oxidative stress in patients with Friedreich ataxia
102. Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2)
103. Hemoglobin and iron evoked oxidative stress in the brain: Protection by bile pigments, manganese and S-nitrosoglutathione
104. Capturing the sublimity of a free radical gas
105. Lack of involvement of neuronal nitric oxide synthase in the pathogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis
106. The role of nitric oxide in neurodegeneration. Potential for pharmacological intervention
107. Anti-inflammatory substances - A new therapeutic option in Alzheimer's disease
108. Neurotoxic Aβ peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro
109. A new structural class of proteasome inhibitors that prevent NF-kappa B activation
110. Pharmacological proteasome inhibitors and their therapeutic potential